Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ONCODESIGN
  6. Summary
    ALONC   FR0011766229

ONCODESIGN

(ALONC)
  Report
Real-time Euronext Paris  -  11:28 2022-12-02 am EST
14.44 EUR    0.00%
10/26Oncodesign : Franchissement de seuil
PU
10/19Oncodesign Services Names Successors as Chairman/CEO Departs
MT
10/19Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
11/28/2022 11/29/2022 11/30/2022 12/01/2022 12/02/2022 Date
14.42(c) 14.44(c) 14.44(c) 14.44(c) 14.44(c) Last
89 323 27 346 90 092 61 070 42 186 Volume
0.00% +0.14% 0.00% 0.00% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2022 45,6 M 47,8 M 47,8 M
Net income 2022 2,90 M 3,04 M 3,04 M
Net cash position 2022 6,55 M 6,87 M 6,87 M
P/E ratio 2022 8,60x
Yield 2022 1,18%
Sales 2023 50,8 M 53,3 M 53,3 M
Net income 2023 3,60 M 3,77 M 3,77 M
Net cash position 2023 12,6 M 13,2 M 13,2 M
P/E ratio 2023 9,22x
Yield 2023 -
Capitalization 99,6 M 105 M 104 M
EV / Sales 2022 2,04x
EV / Sales 2023 1,71x
Nbr of Employees 236
Free-Float 13,8%
More Financials
Company
ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. The group's activity is organized around 3 business units: - Service: discovery, identification and selection of new therapeutic targets in... 
More about the company
Ratings of ONCODESIGN
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ONCODESIGN
10/26Oncodesign : Franchissement de seuil
PU
10/19Oncodesign Services Names Successors as Chairman/CEO Departs
MT
10/19Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund
MT
10/19Oncodesign : Inside Information / Operations of the issuer (acquisitions, sales...)
PU
10/05Oncodesign Precision Medicine to List Directly on Euronext Access + Paris
MT
10/03The General Meeting of Oncodesign authorises the allocation of Oncodesign Precision Med..
AQ
09/30ONCODESIGN : Minutes of the general assembly
CO
09/29Euronext Paris authorises the listing of Oncodesign Precision Medicine shares on Eurone..
AQ
09/29Oncodesign Unit Gains Approval To List On Euronext Access + In Paris
MT
09/28Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine.
CI
09/27Parkinson, Servier exercises the exclusive licensing option on collaborative program wi..
AQ
09/15Oncodesign : announces its results for the first half of 2022
PU
09/15ONCODESIGN : 1st-half-year results
CO
07/21ONCODESIGN : 2nd quarter earnings
CO
07/01Oncodesign Société Anonyme Announces Planned Separation of Its Two Business Areas
CI
More news
News in other languages on ONCODESIGN
03:14aOncodesign : Document AMF CP. 222C2595
12/01Oncodesign : Document AMF CP. 222C2583
11/30Oncodesign : Document AMF CP. 222C2579
11/29Oncodesign : Document AMF CP. 222C2569
11/28Oncodesign : Document AMF CP. 222C2558
More news
Chart ONCODESIGN
Duration : Period :
ONCODESIGN Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCODESIGN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 14,44 €
Average target price 16,67 €
Spread / Average Target 15,5%
EPS Revisions
Managers and Directors
Philippe Genne Chairman & Chief Executive Officer
Arnaud Lafforgue Chief Financial & Administrative Officer
Jan Hoflack Chief Scientific Officer & General Manager
Francis Bichat Technology Director
StÚphane Gerart Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCODESIGN43.25%103
MODERNA, INC.-28.55%67 581
IQVIA HOLDINGS INC.-22.83%40 495
LONZA GROUP AG-33.17%38 281
ALNYLAM PHARMACEUTICALS, INC.38.22%27 139
SEAGEN INC.-20.82%22 538